Experience

Emalex Biosciences

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • Feb 2023 - 11 months

  Chicago, Illinois, United States Emalex Biosciences is developing new treatments for central nervous system movement disorders. Emalex is in late stage development of a new class of drug for patients with Tourette syndrome and other conditions that have limited treatment options.



Paragon Biosciences

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Vice President Business Development

  • May 2019 - Jan 2023

  Chicago, Illinois, United States Identifies, completes due diligence and integrates new products and companies into the Paragon portfolio. Advises early stage Paragon portfolio companies by developing commercial strategies and operational plans. Acting Chief Business Officer at Emalex Biosciences. Paragon is a life science innovator that creates, invests in and builds bioscience companies. We solve complex challenges by advancing science. Paragon focuses on four areas of life science innovation including artificial… Show more Identifies, completes due diligence and integrates new products and companies into the Paragon portfolio. Advises early stage Paragon portfolio companies by developing commercial strategies and operational plans. Acting Chief Business Officer at Emalex Biosciences. Paragon is a life science innovator that creates, invests in and builds bioscience companies. We solve complex challenges by advancing science. Paragon focuses on four areas of life science innovation including artificial intelligence, gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies in development. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit: ParagonBioSci.com. Show less

• CEO

  • Aug 2018 - May 2019

  Co-founder and first CEO of Emalex Biosciences. Emalex is developing ecopipam, a new drug in development for pediatric Tourette's Syndrome and Child Onset Fluency Disorder.

• Senior Vice President, Portfolio Management

  • Oct 2017 - Aug 2018

  Evaluate potential product licences and company acquisitions in the biotechnology sector.



Marathon Pharmaceuticals

• United Kingdom
• Events Services

• Vice President Sales and Marketing

  • May 2016 - May 2017

  Northbrook, IL Responsible for all aspects of commercializing Marathon's orphan pharmaceutical products, including sales, marketing, managed care and patient advocacy.



Anagin

• United States

• CEO

  • Jul 2015 - May 2016

  Indianapolis, Indiana Area



OPKO Health, Inc.

• United States
• Biotechnology Research
• 100 - 200 Employee

• General Manager Sales and Marketing, OPKO Renal

  • Aug 2013 - Aug 2014

• EVP Sales and Marketing, OPKO Renal & Marketing Coordinator, OPKO Health

  • Mar 2013 - Aug 2013



Cytochroma Inc.

• Chief Operating Officer

  • Mar 2010 - Mar 2013

  OPKO acquired Cytochroma in March 2013

• VP Commercial Operations

  • Jun 2006 - Mar 2010



Proventiv Therapeutics

• United States
• Pharmaceutical Manufacturing

• VP Marketing & Commercial Operations

  • Sep 2005 - Jun 2006

  Founder/owner of Proventiv Therapeutics. Cytochroma acquired Proventiv in June 2006.



Bone Care International

• Senior Director of Marketing

  • Sep 2004 - Aug 2005

  Genzyme acquired Bone Care in July 2005

• Director of Marketing

  • Aug 2003 - Sep 2004


Abbott
• United States
• Hospitals and Health Care
• 700 & Above Employee
• Senior Product Marketing Manager

  • Mar 2001 - Aug 2003


Knoll Pharmaceuticals - division of BASF

• Associate National Sales Director

  • Jul 2000 - Mar 2001

  Abbott Laboratories acquired Knoll in March 2001